Deans' stroke musings: NT-proBNP (N-terminal pro-B-type natriuretic peptide) and the risk of stroke: Results from the BiomarCaRE Consortium

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Saturday, February 23, 2019

NT-proBNP (N-terminal pro-B-type natriuretic peptide) and the risk of stroke: Results from the BiomarCaRE Consortium

Whatever this means. Ask your doctor. Does this cause a stroke or just a correlation?

NT-proBNP (N-terminal pro-B-type natriuretic peptide) and the risk of stroke: Results from the BiomarCaRE Consortium

Stroke — Di Castelnuovo A, et al. | February 22, 2019

In this study using data from the BiomarCaRE Consortium, researchers assessed the correlation between N-terminal pro-B-type natriuretic peptide (NT-proBNP) and stroke, and determined the predictive value beyond a panel of risk factors established. Overall, they noted a positive association of NT-proBNP levels with ischemic and hemorrhagic stroke risk, irrespective of several other risk factors and conditions in this cohort of stroke-free European adults. Furthermore, the addition of NT-proBNP to established risk scoring variables improved stroke prediction with a medium size effect.

Methods

The study sample consisted of 58,173 stroke-free individuals (50% men; mean age: 52 years) from 6 community-based cohorts.
They measured NT-proBNP in the central Biomarkers for Cardiovascular Risk Assessment in Europe laboratory.
Total stroke and subtypes of stroke (ischemic/hemorrhagic) comprised outcomes.

Results

In all, 1,550 stroke events (1,176 ischemic) occurred during a median follow-up time of 7.9 years.
An association of increasing quarters of the NT-proBNP distribution with increasing risk of stroke was evident.
Investigators found that individuals in the highest NT-proBNP quarter (NT-proBNP > 82.2 pg/mL) had a twofold (95% CI, 75% to 151%) greater risk of stroke vs those in the lowest quarter (NT-proBNP < 20.4 pg/mL).
When adjusted for interim coronary events during follow-up, the association remained unchanged; although it was somewhat heterogeneous across cohorts, it was highly homogeneous depending on the cardiovascular risk profile or stroke subtypes.
The addition of NT-proBNP to a reference model elevated the C-index discrimination measure by 0.006 (P=0.0005), and resulted in a categorical net reclassification improvement of 2.0% in events and 1.4% in nonevents and an integrated discrimination improvement of 0.007.

Read the full article on Stroke